Ottimo Pharma is a private biotechnology company, co-founded in 2020 by Medicxi and Jonny Finlay, focused on the development of pioneering innovative cancer therapies for solid tumors. The Company's lead program, Jankistomig, is a PD1-VEGFR2 bi-functional antibody designed to target both immune checkpoint inhibition and angiogenesis in a single IgG therapy. By advancing this dual-pathway approach, Ottimo Pharma aims to improve cancer treatment outcomes and reduce overall healthcare burden. The Company boasts a world-class leadership team, including David Epstein as Chair and CEO, Mehdi Shahidi as Head of Development and CMO, and James Sabry as Vice-Chair of the Board. Ottimo Pharma anticipates filing an IND in late 2025.
Company Details
- Employees
- 20
- Founded
- -
- Address
- Manager Jobs
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://ottimopharma.com
- Keywords
- in #immuno-oncology.
Ottimo Pharma Questions
Ottimo Pharma's website is http://ottimopharma.com
Ottimo Pharma's LinkedIn profile is https://www.linkedin.com/company/ottimo-pharma
Ottimo Pharma has
20 employees.
View email and phone details for 20
employees at Ottimo Pharma.
Ottimo Pharma's industry is
Biotechnology Research
Ottimo Pharma's top competitors are
Aerovate Therapeutics, Inc.,
Glycomimetics,
Chimagen Biosciences,
Nuwellis, Inc.,
Monte Rosa Therapeutics,
Axonis Therapeutics,
Jade Biosciences,
Kivu Bioscience,
Medicxi,
Crescent Biopharma.
Ottimo Pharma's categories are Biotechnology Research
Ottimo Pharma's founding year is 2020
